Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Kamada Ltd (KMDA)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 199,287
  • Shares Outstanding, K 40,260
  • Annual Sales, $ 102,830 K
  • Annual Income, $ 6,900 K
  • 36-Month Beta 1.17
  • Price/Sales 1.90
  • Price/Cash Flow 18.77
  • Price/Book 2.17

Price Performance

See More
Period Period Low Period High Performance
1-Month
4.50 +10.00%
on 05/09/18
5.04 -1.79%
on 05/22/18
+0.25 (+5.32%)
since 04/24/18
3-Month
4.35 +13.79%
on 04/02/18
5.35 -7.48%
on 02/27/18
-0.23 (-4.35%)
since 02/23/18
52-Week
3.75 +32.00%
on 08/16/17
8.61 -42.51%
on 06/01/17
-2.15 (-30.28%)
since 05/24/17

Most Recent Stories

More News
Kamada Ltd to Host Earnings Call

NEW YORK, NY / ACCESSWIRE / May 15, 2018 / Kamada Ltd (NASDAQ: ) will be discussing their earnings results in their Q1 Earnings Call to be held on May 15, 2018 at 8:30 AM Eastern Time.

KMDA : 4.95 (+2.06%)
Kamada Reports Financial Results for First Quarter of 2018

-- U.S. Launch of KEDRAB(R) [Human Rabies Immune Globulin (HRIG)] Represents Significant Company Milestone

KMDA : 4.95 (+2.06%)
Kamada to Announce First Quarter 2018 Financial Results and Host Conference Call on May 15

Kamada Ltd. (NASDAQ:KMDA) (TASE:KMDA), a plasma-derived protein therapeutics company, today announced that it will release financial results for the quarter ended March 31, 2018, prior to the open of the...

KMDA : 4.95 (+2.06%)
Kedrion Biopharma and Kamada Announce KEDRAB(R) (Rabies Immune Globulin [Human]) Now Shipping; Distribution Timed to Meet Spring/Summer Demand for Product

Kedrion Biopharma and Kamada Ltd. (NASDAQ:KMDA) (TASE:KMDA), two leading human-derived protein therapeutics companies, announced today that KEDRAB(R) [Rabies Immune Globulin (Human)]...

KMDA : 4.95 (+2.06%)
Israel-based Medical Cannabis Solutions Provider, Kanabo Research, has Signed an Agreement With Constance Therapeutics From the US

Israeli startup Kanabo Research, which develops clinical solutions for extraction and vaporization of medical cannabis, announces it is entering an agreement with Constance Therapeutics, a US-based medical...

KMDA : 4.95 (+2.06%)
Kamada Received Feedback from FDA on Proposed Phase 3 Protocol for Inhaled Alpha-1-Antitrypsin for Treatment of Alpha-1 Antitrypsin Deficiency Disease

Kamada Ltd. (the "Company") (Nasdaq:KMDA) (TASE:KMDA), a plasma-derived protein therapeutics company, today announced that the Company recently received feedback from the U.S. Food and Drug Administration...

KMDA : 4.95 (+2.06%)
Kamada Reports Financial Results for Fourth Quarter and Full-Year 2017

-- Total Revenues for Fiscal 2017 were $102.8 Million, up 33% Over Fiscal 2016; Exceeded Full-Year Revenue Guidance of $100 Million

KMDA : 4.95 (+2.06%)
CollPlant Appoints David Tsur as Chairman of the Board

CollPlant (TASE: CLPT, OTC: CQPTY), a regenerative medicine company utilizing its proprietary plant-based rhCollagen technology for tissue repair products (recombinant human, "rhCollagen"), announced...

KMDA : 4.95 (+2.06%)
Kamada Announces Interim Results from Phase 2 Clinical Trial of Intravenous Alpha-1 Antitrypsin Treatment for Prevention of Lung Transplant Rejection

Kamada's IV AAT Demonstrated Favorable Safety and Tolerability Profile in 10 Patients During First Six Months of Treatment, Consistent with Previously Observed Results in Other Indications

KMDA : 4.95 (+2.06%)
Kamada Announces Collaboration with a Consortium of Prominent Hospitals led by The Mount Sinai Hospital to Evaluate its Alpha-1 Antitrypsin Product for Preemption of Steroid Refractory Acute Graft-versus-Host Disease

Study will be Co-Funded by Mount Sinai and Kamada, and will Utilize Biomarkers Developed by Mount Sinai Acute GvHD International Consortium (MAGIC) to Identify Patients at High-Risk

KMDA : 4.95 (+2.06%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Buy with a Weakening short term outlook on maintaining the current direction.

Longer term, the trend strength is Minimum.

See More Share

Trade KMDA with:

Business Summary

Kamada Ltd. is a biopharmaceutical company. It develops, produces and markets therapeutics based on chromatographic purification technology. The company offers bio-therapeutics for specialty proteins, specific immunoglobulins and other prescription medicines. Kamada Ltd. is headquartered in Ness Ziona,...

See More

Key Turning Points

2nd Resistance Point 5.05
1st Resistance Point 5.00
Last Price 4.95
1st Support Level 4.85
2nd Support Level 4.75

See More

52-Week High 8.61
Fibonacci 61.8% 6.75
Fibonacci 50% 6.18
Fibonacci 38.2% 5.61
Last Price 4.95
52-Week Low 3.75

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
New Chart Menu
Right-click anywhere on the chart to open the Interactive Chart menu.

Free Barchart Webinar